Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Cystic fibrosis transmembrane conductance regulator dysfunction in VIP knockout mice.

Alcolado NG, Conrad DJ, Poroca D, Li M, Alshafie W, Chappe FG, Pelis RM, Anini Y, Xu Z, Hamidi S, Said SI, Chappe VM.

Am J Physiol Cell Physiol. 2014 Jul 15;307(2):C195-207. doi: 10.1152/ajpcell.00293.2013. Epub 2014 Jun 4.

2.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

3.

Vasoactive intestinal peptide in pulmonary arterial hypertension.

Said SI.

Am J Respir Crit Care Med. 2012 Apr 1;185(7):786; author reply 786. No abstract available.

PMID:
22467806
4.

Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI.

Br J Pharmacol. 2012 May;166(1):4-17. doi: 10.1111/j.1476-5381.2012.01871.x. Review.

5.

Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy.

Said SI, Hamidi SA.

Pulm Circ. 2011 Jul-Sep;1(3):383-8. doi: 10.4103/2045-8932.87306.

6.

VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.

Hamidi SA, Lin RZ, Szema AM, Lyubsky S, Jiang YP, Said SI.

Respir Res. 2011 Oct 26;12:141. doi: 10.1186/1465-9921-12-141.

7.

17β-estradiol protects the lung against acute injury: possible mediation by vasoactive intestinal polypeptide.

Hamidi SA, Dickman KG, Berisha H, Said SI.

Endocrinology. 2011 Dec;152(12):4729-37. doi: 10.1210/en.2011-1631. Epub 2011 Oct 18.

8.

Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?

Said SI, Hamidi SA, Gonzalez Bosc L.

Eur Respir J. 2010 Apr;35(4):730-4. doi: 10.1183/09031936.00097109.

9.

Animal models of airway hyperresponsiveness.

Said SI.

Eur Respir J. 2009 Jan;33(1):217-8. doi: 10.1183/09031936.00131008. No abstract available.

10.

The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation.

Said SI.

Ann N Y Acad Sci. 2008 Nov;1144:148-53. doi: 10.1196/annals.1418.014.

PMID:
19076374
11.

Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion.

Hamidi SA, Prabhakar S, Said SI.

Eur Respir J. 2008 Jan;31(1):135-9. doi: 10.1183/09031936.00105807.

12.

The discovery of VIP: initially looked for in the lung, isolated from intestine, and identified as a neuropeptide.

Said SI.

Peptides. 2007 Sep;28(9):1620-1. Epub 2007 Jun 12. No abstract available.

PMID:
17719695
13.

Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene.

Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S.

Circulation. 2007 Mar 13;115(10):1260-8. Epub 2007 Feb 19.

PMID:
17309917
14.

Clues to VIP function from knockout mice.

Hamidi SA, Szema AM, Lyubsky S, Dickman KG, Degene A, Mathew SM, Waschek JA, Said SI.

Ann N Y Acad Sci. 2006 Jul;1070:5-9.

PMID:
16888146
15.

Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP.

Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, Chen JJ, Waschek JA, Said SI.

Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L880-6. Epub 2006 Jun 16.

16.

Mediators and modulators of pulmonary arterial hypertension.

Said SI.

Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L547-58. Epub 2006 May 12. Review.

17.

The multiple mediators of neurogenic smooth muscle relaxation.

Said SI, Rattan S.

Trends Endocrinol Metab. 2004 Jul;15(5):189-91. Review.

PMID:
15223046
19.

Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity.

Dickman KG, Youssef JG, Mathew SM, Said SI.

Am J Respir Cell Mol Biol. 2004 Feb;30(2):139-44. Epub 2003 Jul 10.

PMID:
12855408
20.

New evidence for transmitter role of VIP in the airways: impaired relaxation by a catalytic antibody.

Berisha HI, Bratut M, Bangale Y, Colasurdo G, Paul S, Said SI.

Pulm Pharmacol Ther. 2002;15(2):121-7.

PMID:
12090785
21.
22.

Regulation of apoptosis by vasoactive peptides.

Filippatos GS, Gangopadhyay N, Lalude O, Parameswaran N, Said SI, Spielman W, Uhal BD.

Am J Physiol Lung Cell Mol Physiol. 2001 Oct;281(4):L749-61. Review.

23.

Glutamate signalling in the lung.

Said SI, Dey RD, Dickman K.

Trends Pharmacol Sci. 2001 Jul;22(7):344-5. No abstract available.

PMID:
11431027
24.
25.

Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide.

Said SI, Dickman KG.

Regul Pept. 2000 Sep 25;93(1-3):21-9. Review.

PMID:
11033049
26.

NMDA receptor activation: critical role in oxidant tissue injury.

Said SI, Pakbaz H, Berisha HI, Raza S.

Free Radic Biol Med. 2000 Apr 15;28(8):1300-2.

PMID:
10889461
27.

Secretin treatment for autism.

Said SI, Bodanszky M.

N Engl J Med. 2000 Apr 20;342(16):1217-8. No abstract available.

PMID:
10777379
28.

VIP and PACAP in pain and inflammation.

Said SI.

Trends Pharmacol Sci. 2000 Feb;21(2):57. No abstract available.

PMID:
10664608
29.

Attenuation of oxidant-induced lung injury by the synthetic matrix metalloproteinase inhibitor BB-3103.

Foda HD, Rollo EE, Brown P, Pakbaz H, Berisha H, Said SI, Zucker S.

Ann N Y Acad Sci. 1999 Jun 30;878:650-3. No abstract available.

PMID:
10415798
30.

Glutamate receptors and asthmatic airway disease.

Said SI.

Trends Pharmacol Sci. 1999 Apr;20(4):132-4. No abstract available.

PMID:
10322497
31.
32.

Glutamate toxicity in the lung and neuronal cells: prevention or attenuation by VIP and PACAP.

Said SI, Dickman K, Dey RD, Bandyopadhyay A, De Stefanis P, Raza S, Pakbaz H, Berisha HI.

Ann N Y Acad Sci. 1998 Dec 11;865:226-37.

PMID:
9928016
33.

Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.

Maruno K, Absood A, Said SI.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14373-8.

34.

International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA.

Pharmacol Rev. 1998 Jun;50(2):265-70. Review. No abstract available.

35.

N-methyl-D-aspartate receptors are expressed by intrinsic neurons of rat larynx and esophagus.

Robertson BS, Satterfield BE, Said SI, Dey RD.

Neurosci Lett. 1998 Mar 13;244(2):77-80.

PMID:
9572589
36.

Structure-activity studies on VIP: IV. The synthetic agonist helodermin-fragment-(1-28)-amide is a potent VIP-agonist with prolonged duration of tracheal relaxant activity.

Jaeger E, Bauer S, Joyce MW, Foda HD, Berisha HI, Said SI.

Ann N Y Acad Sci. 1996 Dec 26;805:499-504. No abstract available.

PMID:
8993430
37.

VIP inhibits the proliferation of small-cell and nonsmall-cell lung carcinoma.

Maruno K, Said SI.

Ann N Y Acad Sci. 1996 Dec 26;805:389-92; discussion 392-3. No abstract available.

PMID:
8993419
38.

Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury.

Said SI.

Ann N Y Acad Sci. 1996 Dec 26;805:379-87; discussion 387-8. Review. No abstract available.

PMID:
8993418
39.

Characterization of VIP-and helodermin-preferring receptors on rat platelets.

Shima K, Sakakibara H, Said SI.

Regul Pept. 1996 Jul 5;63(2-3):99-103.

PMID:
8837217
40.

Molecules that protect: the defense of neurons and other cells.

Said SI.

J Clin Invest. 1996 May 15;97(10):2163-4. No abstract available.

42.

Neurochemical characterization of intrinsic neurons in ferret tracheal plexus.

Dey RD, Altemus JB, Rodd A, Mayer B, Said SI, Coburn RF.

Am J Respir Cell Mol Biol. 1996 Mar;14(3):207-16.

PMID:
8845170
43.

VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells.

Maruno K, Absood A, Said SI.

Am J Physiol. 1995 Jun;268(6 Pt 1):L1047-51.

PMID:
7541947
44.

Enhancement of extended lung preservation with a vasoactive intestinal peptide-enriched University of Wisconsin solution.

Alessandrini F, Sasaki S, Said SI, Lodi R, LoCicero J 3rd.

Transplantation. 1995 May 15;59(9):1253-8.

PMID:
7762057
45.

Nitric oxide and VIP as co-transmitters of neurogenic relaxation of human airways.

Foda HD, Said SI.

Am J Respir Crit Care Med. 1995 May;151(5):1689-90. No abstract available.

PMID:
7735637
46.

Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins.

Maggi CA, Giachetti A, Dey RD, Said SI.

Physiol Rev. 1995 Apr;75(2):277-322. Review. No abstract available.

PMID:
7724664
48.
49.

Characterization of vasoactive intestinal peptide receptors on rat alveolar macrophages.

Sakakibara H, Shima K, Said SI.

Am J Physiol. 1994 Sep;267(3 Pt 1):L256-62.

PMID:
7943252
50.

Nitric oxide as a mediator of oxidant lung injury due to paraquat.

Berisha HI, Pakbaz H, Absood A, Said SI.

Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7445-9.

Supplemental Content

Support Center